These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19830856)

  • 21. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
    Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
    Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
    Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
    Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive markers of bone turnover and plasma cytokines differ in osteoporotic patients with multiple myeloma and monoclonal gammopathies of undetermined significance.
    Diamond T; Levy S; Smith A; Day P; Manoharan A
    Intern Med J; 2001 Jul; 31(5):272-8. PubMed ID: 11512598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
    Colla S; Zhan F; Xiong W; Wu X; Xu H; Stephens O; Yaccoby S; Epstein J; Barlogie B; Shaughnessy JD
    Blood; 2007 May; 109(10):4470-7. PubMed ID: 17255354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
    Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients.
    Zdzisińska B; Wejksza K; Walter-Croneck A; Turski WA; Kandefer-Szerszeń M
    Leuk Res; 2010 Jan; 34(1):38-45. PubMed ID: 19596432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of the bone marrow plasma cell cytoplasmic light chain ratio in differentiating between multiple myeloma and monoclonal gammopathy of undetermined significance.
    Majumdar G; Grace RJ; Singh AK; Slater NG
    Leuk Lymphoma; 1992 Dec; 8(6):491-3. PubMed ID: 1297481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
    Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
    J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection of serum DKK1 in multiple myeloma and myeloma bone disease].
    Feng X; Deng S; An G; Qin X; Sui W; Zou D; Qiu L; Xu Y
    Zhonghua Xue Ye Xue Za Zhi; 2015 Aug; 36(8):682-5. PubMed ID: 26462639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study.
    Campbell JP; Heaney JLJ; Pandya S; Afzal Z; Kaiser M; Owen R; Child JA; Cairns DA; Gregory W; Morgan GJ; Jackson GH; Bunce CM; Drayson MT
    Lancet Haematol; 2017 Dec; 4(12):e584-e594. PubMed ID: 29146225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Lacy MQ; Donovan KA; Heimbach JK; Ahmann GJ; Lust JA
    Blood; 1999 Jan; 93(1):300-5. PubMed ID: 9864174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of whole-body diffusion MRI and conventional radiological assessment in the staging of myeloma.
    Narquin S; Ingrand P; Azais I; Delwail V; Vialle R; Boucebci S; Tasu JP
    Diagn Interv Imaging; 2013 Jun; 94(6):629-36. PubMed ID: 23683788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
    Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
    Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
    Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
    Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
    Pozzi S; Fulciniti M; Yan H; Vallet S; Eda H; Patel K; Santo L; Cirstea D; Hideshima T; Schirtzinge L; Kuhstoss S; Anderson KC; Munshi N; Scadden D; Kronenberg HM; Raje N
    Bone; 2013 Apr; 53(2):487-96. PubMed ID: 23333523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
    Ely SA; Knowles DM
    Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.